These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35178186)

  • 1. Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells.
    Guo M; He S; Cheng J; Li Y; Dong G; Sheng C
    ACS Med Chem Lett; 2022 Feb; 13(2):298-303. PubMed ID: 35178186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
    Cheng J; Li Y; Wang X; Dong G; Sheng C
    J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel PDEδ Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (ATTEC).
    Bao J; Chen Z; Li Y; Chen L; Wang W; Sheng C; Dong G
    ACS Med Chem Lett; 2024 Jan; 15(1):29-35. PubMed ID: 38229750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity.
    Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
    Chen L; Zhuang C; Lu J; Jiang Y; Sheng C
    J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel KRAS‒PDE
    Chen L; Zhang J; Wang X; Li Y; Zhou L; Lu X; Dong G; Sheng C
    Acta Pharm Sin B; 2022 Jan; 12(1):274-290. PubMed ID: 35127385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
    Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
    Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based development of PDEδ inhibitors.
    Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H
    Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring binding modes of the selected inhibitors to phosphodiesterase delta by all-atom molecular dynamics simulations and free energy calculations.
    Zhong H; Zhang YJ; Shan XB
    J Biomol Struct Dyn; 2019 Jun; 37(9):2415-2429. PubMed ID: 30052144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of a PROTAC induced PDEδ degrader by a biomimetic drug delivery system for enhanced cytotoxicity against pancreatic cancer cells.
    Fan R; He S; Wang Y; Qiao J; Liu H; Galstyan L; Ghazaryan A; Cai H; Feng S; Ni P; Dong G; Li H
    Am J Cancer Res; 2022; 12(3):1027-1041. PubMed ID: 35411249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism.
    Winzker M; Friese A; Koch U; Janning P; Ziegler S; Waldmann H
    Angew Chem Int Ed Engl; 2020 Mar; 59(14):5595-5601. PubMed ID: 31829492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrophobic tagging of small molecules: an overview of the literature and future outlook.
    Zhou Y; Zhou F; Xu S; Shi D; Ding D; Wang S; Poongavanam V; Tang K; Liu X; Zhan P
    Expert Opin Drug Discov; 2024 Jul; 19(7):799-813. PubMed ID: 38825802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
    Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors.
    Jiang Y; Zhuang C; Chen L; Lu J; Dong G; Miao Z; Zhang W; Li J; Sheng C
    J Med Chem; 2017 Nov; 60(22):9400-9406. PubMed ID: 28929751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of
    Armijo ME; Escalona E; Peña D; Farias A; Morin V; Baumann M; Klebl BM; Pincheira R; Castro AF
    Front Pharmacol; 2022; 13():912688. PubMed ID: 35814251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation.
    Xie S; Zhan F; Zhu J; Sun Y; Zhu H; Liu J; Chen J; Zhu Z; Yang DH; Chen ZS; Yao H; Xu J; Xu S
    Angew Chem Int Ed Engl; 2023 Mar; 62(13):e202217246. PubMed ID: 36670545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
    Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H
    Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.
    Peng X; Hu Z; Zeng L; Zhang M; Xu C; Lu B; Tao C; Chen W; Hou W; Cheng K; Bi H; Pan W; Chen J
    Acta Pharm Sin B; 2024 Feb; 14(2):533-578. PubMed ID: 38322348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site.
    Murarka S; Martín-Gago P; Schultz-Fademrecht C; Al Saabi A; Baumann M; Fansa EK; Ismail S; Nussbaumer P; Wittinghofer A; Waldmann H
    Chemistry; 2017 May; 23(25):6083-6093. PubMed ID: 27809361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.
    Salmas RE; Mestanoglu M; Yurtsever M; Noskov SY; Durdagi S
    Biophys J; 2015 Sep; 109(6):1163-8. PubMed ID: 26340817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.